Stocks
Neurocrine Biosciences Financial Statements (NBIX) |
||||||||||
| Neurocrine Biosciencessmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 07.02.2020 | 05.02.2021 | 11.02.2022 | 09.02.2023 | 09.02.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 788.1 | 1 046 | 1 134 | 1 489 | 1 887 | 2 243 | |||
| Operating Income, bln rub | 219.1 | 318.9 | 196.9 | 249.0 | 250.9 | 587.3 | ||||
| EBITDA, bln rub | ? | 226.6 | 336.1 | 218.7 | 264.6 | 416.1 | 619.5 | |||
| Net profit, bln rub | ? | 37.0 | 407.3 | 89.6 | 154.5 | 249.7 | 385.9 | |||
| OCF, bln rub | ? | 152.1 | 228.5 | 256.5 | 339.4 | 389.9 | 476.4 | |||
| CAPEX, bln rub | ? | 14.7 | 10.9 | 23.4 | 16.5 | 28.3 | 36.3 | |||
| FCF, bln rub | ? | 137.3 | 217.6 | 233.1 | 322.9 | 361.6 | 440.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 554.1 | 708.3 | 911.4 | 1 217 | 1 597 | 1 611 | ||||
| Cost of production, bln rub | 7.40 | 10.1 | 14.3 | 23.2 | 39.7 | 44.9 | ||||
| R&D, bln rub | 200.0 | 275.0 | 328.1 | 463.8 | 565.0 | 671.3 | ||||
| Interest expenses, bln rub | 32.0 | 32.8 | 25.8 | 7.10 | 4.60 | 2.20 | ||||
| Assets, bln rub | 1 306 | 1 735 | 2 073 | 2 369 | 3 251 | 3 535 | ||||
| Net Assets, bln rub | ? | 636.9 | 1 126 | 1 374 | 1 708 | 2 232 | 2 719 | |||
| Debt, bln rub | 495.5 | 412.3 | 440.4 | 262.9 | 428.4 | 251.4 | ||||
| Cash, bln rub | 670.5 | 801.0 | 711.3 | 989.3 | 1 032 | 1 228 | ||||
| Net debt, bln rub | -175.0 | -388.7 | -270.9 | -726.4 | -603.2 | -976.6 | ||||
| Ordinary share price, rub | 107.5 | 95.9 | 85.2 | 119.4 | 131.8 | 113.4 | ||||
| Number of ordinary shares, mln | 91.6 | 93.1 | 94.6 | 95.8 | 97.7 | 101.1 | ||||
| Market cap, bln rub | 9 849 | 8 924 | 8 057 | 11 442 | 12 873 | 11 467 | ||||
| EV, bln rub | ? | 9 674 | 8 535 | 7 786 | 10 716 | 12 270 | 10 490 | |||
| Book value, bln rub | 637 | 1 126 | 1 374 | 1 665 | 2 197 | 2 684 | ||||
| EPS, rub | ? | 0.40 | 4.37 | 0.95 | 1.61 | 2.56 | 3.82 | |||
| FCF/share, rub | 1.50 | 2.34 | 2.46 | 3.37 | 3.70 | 4.35 | ||||
| BV/share, rub | 6.95 | 12.1 | 14.5 | 17.4 | 22.5 | 26.6 | ||||
| EBITDA margin, % | ? | 28.8% | 32.1% | 19.3% | 17.8% | 22.0% | 27.6% | |||
| Net margin, % | ? | 4.69% | 38.9% | 7.90% | 10.4% | 13.2% | 17.2% | |||
| FCF yield, % | ? | 1.39% | 2.44% | 2.89% | 2.82% | 2.81% | 3.84% | |||
| ROE, % | ? | 5.81% | 36.2% | 6.52% | 9.05% | 11.2% | 14.2% | |||
| ROA, % | ? | 2.83% | 23.5% | 4.32% | 6.52% | 7.68% | 10.9% | |||
| P/E | ? | 266.2 | 21.9 | 89.9 | 74.1 | 51.6 | 29.7 | |||
| P/FCF | 71.7 | 41.0 | 34.6 | 35.4 | 35.6 | 26.1 | ||||
| P/S | ? | 12.5 | 8.53 | 7.11 | 7.69 | 6.82 | 5.11 | |||
| P/BV | ? | 15.5 | 7.92 | 5.86 | 6.87 | 5.86 | 4.27 | |||
| EV/EBITDA | ? | 42.7 | 25.4 | 35.6 | 40.5 | 29.5 | 16.9 | |||
| Debt/EBITDA | -0.77 | -1.16 | -1.24 | -2.75 | -1.45 | -1.58 | ||||
| R&D/CAPEX, % | 1 356% | 2 523% | 1 402% | 2 811% | 1 996% | 1 849% | ||||
| CAPEX/Revenue, % | 1.87% | 1.04% | 2.06% | 1.11% | 1.50% | 1.62% | ||||
| Neurocrine Biosciences shareholders | ||||||||||
